-
Product Insights
NewNet Present Value Model: Novartis AG’s NIS-793
Empower your strategies with our Net Present Value Model: Novartis AG's NIS-793 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Relapsed Multiple Myeloma Drug Details: Voyager-V1 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Refractory Multiple Myeloma Drug Details: Voyager-V1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Solid Tumor Drug Details: Voyager-V1 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Non-Small Cell Lung Cancer Drug Details: Voyager-V1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To Target...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Recurrent Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Recurrent Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To Target...